The scientific community once relegated the concept of "de-extinction" to the realm of science fiction—a narrative space occupied by cautionary tales like Jurassic Park. Today, however, the Dallas-based startup Colossal Biosciences is challenging that paradigm, not just by attempting to bring the woolly mammoth and the dire wolf back to life, but by building a multi-billion-dollar industrial complex around the genetic technologies required to do so.
As of mid-2026, Colossal is reportedly in advanced discussions to secure a fresh injection of capital that would vault the five-year-old firm to a staggering $20 billion to $30 billion valuation. This follows a previous $10.2 billion valuation set just last year. As the company transitions from a speculative R&D venture into a revenue-generating powerhouse, the narrative surrounding Colossal has shifted from skepticism to a serious analysis of its role as a cornerstone of the modern deep-tech economy.
The Chronology of an Ambition
Colossal’s trajectory has been defined by a rapid, aggressive expansion of its scientific footprint. Founded in 2021 by serial entrepreneur Ben Lamm and renowned geneticist George Church, the company initially focused on the "de-extinction" of the woolly mammoth—a project designed to leverage CRISPR gene-editing to integrate mammoth traits into Asian elephant genomes.
However, the company’s roadmap has evolved significantly since those early days:
- 2021-2023: The company secures initial funding and establishes its Dallas headquarters, focusing on the mammoth and the thylacine (Tasmanian tiger).
- 2024: Colossal shifts public perception by demonstrating that its core technology—advanced synthetic biology and computational genomics—has immediate applications for existing endangered species.
- 2025: The company reveals its intent to "resurrect" the dire wolf. The $10.2 billion valuation confirms that investors are betting on the company’s "platform" rather than just its headline-grabbing animals.
- 2026: The company enters the revenue-generating phase, spinning out subsidiaries and securing government partnerships. Most recently, the bluebuck antelope was added to its portfolio, and the Colossal Foundation began active interventions against transmissible cancers in Tasmanian devils.
The Pillars of Revenue: Beyond the Mammoth
For years, critics questioned how a company dedicated to extinct species could sustain a billion-dollar valuation. The answer lies in the company’s pivot to a diversified revenue model. According to CEO Ben Lamm, the business rests on three distinct pillars: government conservation partnerships, the commercialization of software and hardware spin-offs, and the future development of biodiversity credits.
Government and International Partnerships
Colossal has successfully positioned its technology as a matter of national and international security regarding biodiversity. The U.S. government, through the Department of the Interior, has engaged the firm for its conservation tools. Furthermore, the United Arab Emirates recently solidified this trend by investing $60 million into Colossal’s initiatives, signaling that sovereign wealth is increasingly interested in the "bio-economy."
The Spin-Off Strategy
Perhaps the most significant indicator of Colossal’s maturity is its ability to export its internal research into standalone, venture-backed companies:
- Breaking: A biotech firm focused on utilizing synthetic biology to degrade plastic waste, addressing a critical global environmental crisis.
- Form Bio: A computational biology platform that has successfully raised $30 million, providing the software infrastructure necessary to manage the complex data sets required for gene editing.
- Astromech: An AI-driven predictive modeling company that reached a $2 billion valuation in March 2026. This entity serves as the intelligence engine for the group, applying machine learning to biological outcomes.
By spinning these entities out, Colossal is not merely an "extinction company"; it is a venture factory that creates value in high-growth fields like predictive modeling, environmental remediation, and bioinformatics.
The "Artificial Womb" and the Future of Fertility
One of the most controversial and potentially lucrative segments of Colossal’s research is its development of artificial gestation technology. Originally intended to grow embryos of extinct species to term without the need for a surrogate mother, the technology has immediate, high-value applications in human reproductive health.
CEO Ben Lamm has indicated that this technology is slated to be ready for testing by next year. The implications are profound: if Colossal can provide a safe, viable environment for fetal development outside of the human body, it could revolutionize fertility treatments, potentially addressing global demographic declines and medical complications in high-risk pregnancies.
Scientific and Ethical Implications
The ethics of de-extinction remain a lightning rod for debate. Critics argue that diverting massive amounts of capital toward "resurrecting" animals is an inefficient use of resources that could be better spent on protecting currently endangered species.
Colossal, however, has pivoted to address these concerns directly. By partnering with the University of Tasmania to treat the facial tumor disease devastating the Tasmanian devil population, the company is demonstrating that its tools—gene editing, vaccine development, and population management—are immediately applicable to modern conservation.
Furthermore, the company is looking toward a long-term financial mechanism: biodiversity credits. Similar to the carbon credit market, Colossal aims to create a financial incentive for the restoration of ecosystems. By reintroducing keystone species (like the mammoth, which once maintained the Arctic steppe), the company argues that it can restore lost biological functions that act as natural carbon sinks, creating a sustainable financial loop for ecological restoration.
Market Context: The Deep-Tech Boom
The potential $30 billion valuation for Colossal is not happening in a vacuum. The global capital markets are currently experiencing a surge of interest in "Deep Tech"—sectors where the underlying science is highly complex and the time-to-market is long, but the potential for disruption is total.
From longevity tech (efforts to reverse human aging) to fusion energy and advanced genomics, investors are moving away from purely digital software plays and toward "hard" science. Colossal sits at the intersection of AI and biology—two of the most heavily funded sectors in the modern economy. Because the company has demonstrated an ability to produce real-world, revenue-generating tools (like the software powering Form Bio), it is increasingly viewed as a "must-have" asset for institutional investors seeking exposure to the next industrial revolution: the biological one.
The Road Ahead
Despite the massive scale of its ambitions, Colossal remains a company defined by its ability to deliver on impossible promises. With 55,000 square feet of laboratory space in Dallas, it is a bustling hub of geneticists, AI researchers, and conservationists.
As the company enters this new, potentially record-breaking fundraising round, the industry will be watching closely. The core question remains: will the mammoth, the dodo, and the dire wolf ever actually walk the earth again?
While that remains the company’s most famous "moonshot," the true value of Colossal may have already been realized. By forcing the development of faster gene-sequencing, more accurate AI modeling, and revolutionary gestation technology, the startup has already changed the landscape of modern biology. Whether or not the ancient creatures return, the tools created in the effort to bring them back are likely to define the next century of life sciences.
Colossal Biosciences declined to comment on the ongoing funding reports, but as their footprint grows, their silence is being drowned out by the increasingly loud reality of their scientific and commercial impact.
